<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title><![CDATA[From The Center]]></title><link>http://www.alscenter.org/</link><description><![CDATA[News from the Robert Packard Center for ALS Research at Johns Hopkins]]></description><copyright><![CDATA[2010 by the Robert Packard Center for ALS Research at Johns Hopkins]]></copyright><managingEditor><![CDATA[editor@packardcenter.org]]></managingEditor><webmaster><![CDATA[webmaster@packardcenter.org]]></webmaster><lastBuildDate>Mon, 15 Mar 2010 17:39:22 GMT</lastBuildDate><generator>SiteExecutive v4.1</generator><item><title><![CDATA[License Agreement to Develop New Treatments for Neurological Disease]]></title><link>http://www.alscenter.org/news/rss_from_the_packard_center/10_03_15.html</link><description><![CDATA[Newly formed NeuroTranslational Program at JHU has entered into a licensing agreement with pharmaceutical company Eisai Inc. to discover and develop small molecule glutamate carboxypeptidase II (GCPII) inhibitors.]]></description><guid isPermaLink="true">http://www.alscenter.org/news/rss_from_the_packard_center/10_03_15.html</guid><pubDate>Mon, 15 Mar 2010 17:38:45 GMT</pubDate></item><item><title><![CDATA[NIH Grant Funds Study on Stem Cells from ALS Patients]]></title><link>http://www.alscenter.org/news/rss_from_the_packard_center/10_02_22.html</link><description><![CDATA[A two-year $3.7 million stimulus grant from the National Institutes of Health will allow Johns Hopkins neurologist Jeffrey Rothstein to expand on his research into the nerve- and muscle-wasting disease amyotrophic lateral sclerosis, or ALS.]]></description><guid isPermaLink="true">http://www.alscenter.org/news/rss_from_the_packard_center/10_02_22.html</guid><pubDate>Tue, 23 Feb 2010 18:32:33 GMT</pubDate></item><item><title><![CDATA[Project A.L.S. and Packard Center Take Aim at ALS with $15 Million Program]]></title><link>http://www.alscenter.org/news/research_news_archive/10/10_01_29.html</link><description><![CDATA[Project A.L.S. and the Robert Packard Center for ALS Research at Johns Hopkins will partner on P2 ALS, a $15 million initiative designed to advance ALS research exponentially over the next three years.]]></description><guid isPermaLink="true">http://www.alscenter.org/news/research_news_archive/10/10_01_29.html</guid><pubDate>Fri, 29 Jan 2010 15:03:47 GMT</pubDate></item><item><title><![CDATA[Why the New Antisense Trials Make Sense for ALS]]></title><link>http://www.alscenter.org/news/research_news_archive/10/10_01_28.html</link><description><![CDATA[This February, a new entry in the ALS clinical trials system will have top scientists watching intently for results. It’s the start of human tests of a therapy based on a totally new principle—one that works by silencing mutant genes.]]></description><guid isPermaLink="true">http://www.alscenter.org/news/research_news_archive/10/10_01_28.html</guid><pubDate>Thu, 28 Jan 2010 16:54:15 GMT</pubDate></item><item><title><![CDATA[Stem Cells Can Form Correct Motor Connections in the Brain]]></title><link>http://www.alscenter.org/news/research_news_archive/10/10_01_19.html</link><description><![CDATA[New animal study shows neurons developed from stem cells successfully wired with other brain regions, including those tied to movement.]]></description><guid isPermaLink="true">http://www.alscenter.org/news/research_news_archive/10/10_01_19.html</guid><pubDate>Wed, 20 Jan 2010 14:54:48 GMT</pubDate></item><item><title><![CDATA[Zumbathon]]></title><link>http://www.alscenter.org/get_involved/events/event_syndication/10_01_23.html</link><description><![CDATA[Experience up to 3 hours of Zumba for only $10 at Interactive Fitness in Timonium. Saturday, January 23, 2010, 9am-12pm]]></description><guid isPermaLink="true">http://www.alscenter.org/get_involved/events/event_syndication/10_01_23.html</guid><pubDate>Wed, 30 Dec 2009 02:33:58 GMT</pubDate></item><item><title><![CDATA[New Blood Test for ALS Damage Should Tighten Animal Trials]]></title><link>http://www.alscenter.org/news/rss_from_the_packard_center/09_12_15.html</link><description><![CDATA[Right now, there's no quick, reliable way to tell if something has stopped or slowed ALS down. Packard expertise helps bring an easily measured biomarker closer.]]></description><guid isPermaLink="true">http://www.alscenter.org/news/rss_from_the_packard_center/09_12_15.html</guid><pubDate>Sun, 27 Dec 2009 02:47:41 GMT</pubDate></item><item><title><![CDATA[New ALS Drug Still In The Pipeline After Phase II Trial]]></title><link>http://www.alscenter.org/news/rss_from_the_packard_center/09_12_22.html</link><description><![CDATA[A drug already used to treat symptoms of epilepsy has potential to slow the muscle weakening that comes with amyotrophic lateral sclerosis (ALS).]]></description><guid isPermaLink="true">http://www.alscenter.org/news/rss_from_the_packard_center/09_12_22.html</guid><pubDate>Sun, 27 Dec 2009 02:41:00 GMT</pubDate></item></channel></rss>
